Sugumar Hariharan, Lancefield Terase F, Andrianopoulos Nick, Duffy Stephen J, Ajani Andrew E, Freeman Melanie, Buxton Brian, Brennan Angela L, Yan Bryan P, Dinh Diem T, Smith Julian A, Charter Kerrie, Farouque Omar, Reid Christopher M, Clark David J
Department of Cardiology, Austin Hospital, Melbourne, Victoria, Australia.
Centre of Cardiovascular Research and Education in Therapeutics (CCRE), Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Int J Cardiol. 2014 Mar 15;172(2):442-9. doi: 10.1016/j.ijcard.2014.01.096. Epub 2014 Jan 24.
Comorbidities, such as diabetes, affect revascularization strategy for coronary disease. We sought to determine if the degree of renal impairment affected long-term mortality after percutaneous coronary intervention (PCI) compared to coronary artery bypass grafting (CABG) in patients with multi-vessel coronary disease (MVD).
8970 patients with MVD undergoing revascularization between 2004 and 2008, in two multi-center parallel PCI and CABG Australian registries were assigned to three groups based on their estimated glomerular filtration rate (eGFR)≥60 mL/min/1.73 m2 (n=1678:839), 30-59 mL/min/1.73 m2 (n=452:226) and <30 mL/min/1.73 m2 (n=74:37). We used 2:1 propensity matching to compare 3306 patients undergoing primary CABG versus PCI. Shock, myocardial infarction (MI)<24 h, previous CABG, valve surgery or PCI were exclusions. Long-term mortality (mean 3.1 years) was compared with Cox-proportional hazard-adjusted modeling. Observed long-term mortality rates (CABG vs. PCI) were 4.5% vs. 4.3% p=0.84, 12.8% vs. 17.3% p=0.12, and 23.0% vs. 40.5% p=0.05 in the three strata, respectively. In patients with eGFR≥60 mL/min/1.73 m2, long-term mortality between PCI and CABG (HR 0.99, 95% CI 0.65-1.49, p=0.95) was similar. However, amongst patients with eGFR 30-59 mL/min/1.73 m2, there was a significant mortality hazard with PCI (HR 2.00, 95% CI 1.32-3.04, p=0.001). In patients with eGFR<30 mL/min/1.73 m2, there was a trend for hazard with PCI (HR 1.66, 95% CI 0.80-3.46, p=0.17).
Long-term mortality in MVD patients with preserved renal function was very low and similar between PCI and CABG. However there was a long-term mortality hazard associated with PCI amongst patients with moderate renal impairment.
合并症,如糖尿病,会影响冠心病的血运重建策略。我们试图确定在多支血管冠心病(MVD)患者中,与冠状动脉旁路移植术(CABG)相比,肾功能损害程度是否会影响经皮冠状动脉介入治疗(PCI)后的长期死亡率。
2004年至2008年间,在两个多中心平行的澳大利亚PCI和CABG注册研究中,8970例接受血运重建的MVD患者根据其估计肾小球滤过率(eGFR)被分为三组:≥60 mL/min/1.73 m2(n = 1678:839)、30 - 59 mL/min/1.73 m2(n = 452:226)和<30 mL/min/1.73 m2(n = 74:37)。我们采用2:1倾向匹配法比较3306例接受初次CABG与PCI的患者。排除休克、心肌梗死(MI)<24小时、既往CABG、瓣膜手术或PCI患者。采用Cox比例风险调整模型比较长期死亡率(平均3.1年)。在三个分层中,观察到的长期死亡率(CABG vs. PCI)分别为4.5% vs. 4.3%,p = 0.84;12.8% vs. 17.3%,p = 0.12;23.0% vs. 40.5%,p = 0.05。在eGFR≥60 mL/min/1.73 m2的患者中,PCI和CABG之间的长期死亡率(HR 0.99,95%CI 0.65 - 1.49,p = 0.95)相似。然而,在eGFR为30 - 59 mL/min/1.73 m2的患者中,PCI存在显著的死亡风险(HR 2.00,95%CI 1.32 - 3.04,p = 0.001)。在eGFR<30 mL/min/1.73 m2的患者中,PCI存在死亡风险趋势(HR 1.66,95%CI 0.80 - 3.46,p = 0.17)。
肾功能 preserved的MVD患者长期死亡率非常低,PCI和CABG之间相似。然而,中度肾功能损害患者中PCI存在长期死亡风险。 (注:原文中“preserved”疑似有误,可能是“preserved renal function”表示“肾功能正常” )